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1. Introduction  
The Churg-Strauss syndrome (CSS), also called allergic granulomatosis and angiitis, is a 
multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral 
blood eosinophilia. CSS is classified as a vasculitis of the small and medium sized arteries, 
which commonly involve the lung, the skin and the peripheral nerves and it is associated to 
ANCA in 40-60 percent (Sinico & Bottero 2009). Among the three anti-neutrophil cytoplasmic 
antibodies (ANCA)-associated vasculitides (CSS, Wegener's granulomatosis, and microscopic 
polyangiitis), CSS is least common. In the general population, the frequency of the disorder 
has been estimated at 2.4–6.8 per 1 000 000 patient-years, while the incidence of CSS in asthma 
drug users has been estimated to be 14-52 per million person-years (Watts RA et al. 2000). The 
mean age at diagnosis of CSS is 40 years, with no gender predominance.  
Diagnosis of Churg-Strauss syndrome can be difficult, because the syndrome may arise at 
first as a common association between asthma and allergic rhinitis. Because asthma itself 
might be associated with sinusitis, occasional pulmonary infiltrates (eg, mucus plugging, 
atelectasis, or intermittent infection), and corticosteroid dependency, a clear diagnosis of 
Churg-Strauss syndrome might not be made until extra respiratory system become 
involved, such as the abdominal viscera, heart, or nervous system. 
2. Diagnostic criteria 
The ACR has established six criteria for the classification of CSS in a patient with 
documented vasculitis (Masi AT et al.1990). The presence of four or more of these criteria 
had a sensitivity of 85 percent and a specificity of 99.7 percent for CSS: 
- Asthma (a history of wheezing or the finding of diffuse high pitched wheezes on 
expiration) 
- Greater than 10 percent eosinophils on the differential leukocyte count 
- Mononeuropathy (particularly multiplex) or polyneuropathy 
- Migratory or transient pulmonary opacities detected radiographically 
- Paranasal sinus abnormality 
- Biopsy containing a blood vessel showing the accumulation of eosinophils in extra-
vascular areas. 
Chapel Hill Consensus Conference (Jennette JC et al 1994) analyzed pathological and clinical 
findings to define CSS as an eosinophil-rich and granulomatous inflammation involving the 
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respiratory tract and necrotising vasculitis affecting small-to-medium-size vessels and 
associated with asthma and eosinophilia. 
A clinical approach to define Churg-Strauss syndrome was that of Lanham and colleagues 
(Lanham JG 1984) at the Hammersmith Hospital, London, who have defined the disorder as 
a syndrome including: 
(1) a history of asthma; (2) blood eosinophilia (>1500 cells/mcl); and (3) systemic vasculitis 
involving two or more organs. 
Unfortunately, the involvement of two or more than two organs is difficult to assess without 
doing a biopsy—an invasive procedure in patients who may be very ill and need initiation 
of aggressive systemic corticosteroid treatment. An important clinical clue to the diagnosis 
of CSS in patients with chronic rhinosinusitis associated with the eosinophilic phenotype of 
asthma is to pay particular attention to every extra-respiratory manifestations , such as 
paresthesias, skin eruption or systemic symptoms. 
The detection of ANCA, particularly P-ANCA (perinuclear pattern at indirect 
immnofluorescence) with anti-myeloperoxidase (anti MPO) specificity (ELISA assay) 
supports the diagnosis, but ANCA are present in only 35-40 % of patients.  
3. The phases of CSS 
In many patients, the disease follows a characteristic 3-stage course (Lanham JG 1984). 
Asthma and/or allergic rhinitis with or without nasal polyposis precedes full development 
of the syndrome, usually by many years. Significant blood eosinophilia, an unusual finding 
in uncomplicated asthma may also be present at this early stage of disease. 
In the next stage, tissue infiltration by eosinophils, with or without granuloma formation, 
occurs in various organs, particularly in the upper and lower respiratory tract, the 
gastrointestinal tract, and the myocardium. Clinically, this stage is characterized by 
symptoms and findings related to tissue eosinophilia. Vasculitis is still absent at this stage. 
The third phase of disease is defined by the onset of systemic vasculitis, which usually 
develops several years after the onset of asthma. Necrotizing small-vessel vasculitis may be 
clinically apparent in peripheral nerves (mono- or polyneuropathy, mononeuritis 
multiplex), skin (purpura), and kidneys (necrotizing and crescentic glomerulonephritis) 
(Gross WL. 2002).  
Although these phases are conceptually helpful, they might not be clinically identifiable in 
all patients, and they often do not occur in sequence. The eosinophilic phase of the disease is 
the most challenging phase from the clinical diagnostic point of view. Tissue infiltration by 
eosinophils is observed in a variety of other conditions, including drug hypersensitivity, 
parasitic infections, malignancies, and allergic conditions. Chronic eosinophilic pneumonia 
(PEC) which frequently occurs in association with asthma and peripheral blood 
eosinophilia, may mimic CSS, with the only differences that necrotizing lesions are less 
apparent. Gastrointestinal eosinophilic disease may cause important symptoms even in the 
absence of vasculitis, while the development of vasculitis can be revealed by catastrophic 
abdominal complications, such as bowel perforation. Thus, there is no general consensus for 
classifying patients with this non-vasculitic second stage of CSS. 
Another intriguing aspect is the differential diagnosis with the hypereosinophilic syndrome 
(HES). HES is defined by severe blood eosinophilia (>1.5 X 109 cells/litre for > 6 months) 
and tissue infiltration by eosinophils resulting in organ dysfunction after exclusion of other 
causes of hypereosinophilia. Diffuse necrosis and vasculitis are generally absent, and a 
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history of asthma is rare in HES. Nevertheless, the clinical differentiation of HES from CSS is 
not always easy, particularly in the absence of apparent small-vessel vasculitis. Besides 
eosinophilia, HES and CSS share many common clinical features, such as neuropathy, 
dyspnea, fatigue, fever, and skin rashes. The role of eosinophilic granulocytes as the 
primary effector cells and the clinical similarities, may suggest a common etiology and 
pathogenesis for CSS and HES (Roufosse FE et al 2007), and raises the question whether CSS 
is simply the third disease stage of HES in patients with asthma. 
Immunophenotype, T-cell clonal and cytogenetic studies, and molecular analysis to detect 
Fip1-like 1 (FIP1L1)–platelet-derived growth factor receptor-a (PDGFRA) gene fusion , the 
molecular markers in the most common form of HES, should therefore probably be 
performed for every patient suspected of having CSS, at least those who are ANCA-negative 
and/or without histologically proven vasculitis. 
4. Etiology 
4.1 The controversial association of drug treatment with CSS 
Several exogenous triggering factors for the onset of disease have been suspected, including 
vaccinations, desensitizations, and drugs, such as macrolides, carbamazepine, quinine, and 
anti-asthma medications, like leukotriene-receptor antagonists (LTRAs) (Bibby et al 2010) 
and omalizumab, a monoclonal anti IgE antibody recently approved for severe allergic 
asthma (Wechsler ME et al 2009). It is more likely that anti-asthma medications unmask the 
underlying disease rather than cause the disease.  
Systemic glucocorticoid withdrawal is facilitated by LTRAs, as well by increased dose of 
inhaled corticosteroids or omalizumab, leading CSS disease manifestations in those patients 
with undiagnosed but escalating CSS. 
However, it is difficult to completely exclude the possibility that LTRAs play a causal role in 
the development of CSS in some patients. 
An unusual CSS-like vasculitis has been associated with the use of free base cocaine (Orriols 
R et al. 1996) . The diagnosis of CSS in patients who use cocaine is a complicated issue 
because both acute and chronic eosinophilic pneumonia are manifestations of cocaine 
toxicity and antineutrophil cytoplasmic antibodies are detected in the majority of patients 
with cocaine-induced midline destructive lesions of the nose, even if the ANCAs associated 
with cocaine use are generally cANCA (cytoplamic pattern at indirect immnofluorescence), 
with anti-proteinase 3 (anti Pr3) specificity (ELISA assay).  
4.2 Genetics 
Whereas asthma often clusters in families, familial cases of CSS are exceptional, diminishing 
the role the genes may play in favor of environmental factors . Some studies, pooling CSS 
patients with WG and MPA, found a not significant association with a lower frequency of 
HLA-DRB1*03(Boki KA, 1997). More recent genetic studies suggested some predisposing 
hereditary factors, like the HLA-DRB1*04 and HLA-DRB1*07 alleles and the HLA-DRB4 
gene, which would be more frequent in Churg-Strauss syndrome patients than in healthy 
controls (Vaglio A. et al 2007). HLA-DRB4 positive patients were associated with a higher 
number of vasculitis symptoms, in particular in the ANCA positive group. The interleukin 
IL10.2 haplotype, which is associated with enhanced IL-10 expression, and possibly the 
CD226 Gly307Ser polymorphism have been suggested as important genes in CSS 
(Wieczorek S et al, 2010) An attempt to undiscover the complex genome transcription profile 
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of CSS has been performed by using focused microarray analysis of PBMCs in which a 
limited number of mRNA has been tested. Up regulation of a different number of PREP 
(Prolyl endopeptidase) genes suggest an enhanced immune response that might cause 
vascular damage (Tougan T et al, 2008). 
5. Immunopatogenesis 
The actual pathogenetic model of CSS is mainly incomplete.  
The prodromic phase, characterized by asthma and allergic manifestations is thought to be 
related to a prominent Th2-lymphocyte activity. The second phase is characterized by 
eosinophilic infiltration into tissues. Eosinophils, when activated by Th2 related cytokines 
(interleukin (IL)-4, IL-5, IL-10 and IL-13), release major basic protein, eosinophilic cationic 
protein, eosinophil derived neurotoxin and eosinophil peroxidase, which may cause direct 
tissue and endothelial damage, and trigger the oxidative stress cascade.  
The systemic phase, with the development of necrotizing vasculitis is associated with 
ANCA production, with the contribution of eosinophils. It is thought that IgE containing 
immune complexes (Manger BJ et al, 1985), surrounded by eosinophils and / or ANCA 
production would amplify and/or facilitate the development of vasculitic lesions in some 
patients.  
5.1 The role of T cells 
5.1.1 T helper cells 
The pathogenic role of T cells in Churg Strauss Syndrome is suggested by different 
observations. First, T cells are commonly present in biopsies of active lesions, both vasculitic 
and granulomatous. A study of the clinicopathological features of neuropathy associated 
with the syndrome showed that CD8+ and CD4+ T cell outnumber eosinophils in neuronal 
biopsy specimen, suggesting a T-cell mediated damage of epineural vessels. (Hattori N et al, 
1999). 
Second, CSS shows a strong Th2-type immune response; T cell lines from CSS patients, 
generated in vitro by polyclonal stimulation, are polarized towards a Th2 phenotype (IL-4 
and IL-13), which may explain the eosinophilia, the hallmark of the disease. The same cells 
have also been shown to release significant amounts of IFN-, which may be related to the 
granuloma formation (Kiene M et al, 2001). Current understanding of CSS implies that Th2-
cells drive the activation of eosinophils, which secrete a variety of harmful mediators such 
as major basic protein, ECP, and eosinophil-derived neurotoxin. Interleukin-5 produced by 
Th2-cells is one of the key inducers of eosinophilia in CSS. Another molecule, which is 
supposed to play an important role , is CCL17/thymus and activation–related chemokine 
(TARC), a CC chemokine secreted from peripheral blood mononuclear cells (PBMCs) and 
various subsets of monocyte-derived dendritic cells (DCs). It is the ligand for CCR4 and 
CCR8 chemokine receptors on human PBMCs and T cells, respectively. Given the 
expression profile of its receptors and the ability of CCL17/TARC to selectively induce 
migration of CD4+CD45RO+ T cells producing Th2 cytokines , it may be crucial for the 
specific recruitment and trafficking of Th2 cells, which are known to be activated in CSS. 
CCL17/TARC in the affected tissue of CSS patients is readily identified by immuno-
histochemical analysis, thus it may contribute to CSS pathogenesis by recruitment of Th2 
cells into affected tissue (Dallos T et al, 2010).  
 
Churg Strauss Syndrome: Clinical and Pathogenetic Approach to Therapy 
 
239 
T cells contribute to the pathogenesis of CSS by secretion of cytokines and chemokines, but 
they need to be functionally activated to accomplish this. Increases in serum concentration 
of eosinophilic cationic protein (suggesting eosinophil activation) and soluble 
thrombomodulin (indicating endothelial-cell damage) have been shown to correlate with 
soluble IL-2 receptor, suggesting T-cell activation (Schmitt WH et al, 1998). 
5.1.2 T regulatory cells and Th17 populations 
During the past decade, CD4+CD25+ regulatory T-cells (Tregs) have emerged as key players 
in the development of immunological tolerance. It has been proposed that onset of 
autoimmune diseases is determined by a dysfunction/deficiency of naturally occurring Treg 
cells and by an imbalance between self-reactive T-cells and natural Tregs. CSS patients at 
disease onset or relapse have fewer T regulatory cell subsets (CD4+CD25+ T cells) 
producing IL-10 (Tr1) than the patients in remission or patients with asthma. Moreover, the 
number of organs involved has been shown to correlate negatively with the number of T reg 
cells. This lower percentage of T reg cells during active CSS would, at least in part, explain 
the breakdown of immunological tolerance that leads to CSS onset. According to this 
hypothesis, maintenance of the numbers of regulatory T cells in patiens with chronic 
eosinophilic pneumonia (CEP) with asthma might inihibit CSS development (Tsurikisawa N 
et al, 2008).  
T helper 17 cells (Th17) are a newly discovered subset of T helper cells producing 
interleukin 17 (IL-17) which are thought to play a role in inflammation and tissue injury 
(Steinman L, 2007). The percentage of Th17 in peripheral blood has been reported to be 
significantly higher in patients with active CSS than in healthy subjects or in patients with 
inactive disease (Saito H et al, 2009). An imbalance in the Th17/Treg ratio is associated to 
the immune suppressive degree of treated CSS patients (Jakiela B et al, 2011). These findings 
suggest Th17 and regulatory T cells may play important roles in the pathogenesis of CSS. 
5.1.3 CD4+ and CD8+ T cell subsets 
T cells normally recognize antigens as short peptides using their T cell receptor (TCR) 
specifically binding to MHC molecules on the surface of antigen-presenting cells. TCR 
recognition of the antigen results in stimulation and clonal proliferation of the activated T 
cell. Oligoclonal expanded T cells reflect conventional antigen (Ag) stimulation involving 
one every million T cells. In immune-mediated diseases where the antigen is unknown, 
studies of the TCR repertoire of expanded T cells can give clues to the nature of the antigen. 
Superantigen (SAg) are peptides that differ in several ways from conventional peptide 
antigens, in that they characteristically activate a much higher proportion of T cells than 
conventional antigens. Typically SAgs will stimulate up to 20% of circulating T cells. SAg 
stimulation of T cells bearing specific V (Wei S et al, 1997) T-cell receptors (TCR) results in 
the polyclonal expansion of selected V families in CD4+ and CD8+ cells, followed by T cell 
restricted deletion (Fraser J et al, 2000). Whether lymphocytes activation in CSS is induced 
by antigen (Ag) or superantigen (SAg) is not presently known. Oligoclonal expanded T cell 
have been actually found in CSS patients by immunoscope technique, but it is not known 
whether these expanded T cells are CD4+ or CD8+ (Muschen M et al, 1999). Immunoscope-
based analysis of TCR repertoires in 7 CSS patients revealed clonal expansion (one or more 
dominant picks) of V 21(7/7) , V 11 (3/7) and V 12 (2/7) families. 
One or more Vβ families were found numerically expanded by flow cytometry among CD8 
T cells population of all CSS patients who were investigated, both in clinical remission and 
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during treatment for active disease. These expanded T cells were mostly represented by 
CD8+ lymphocytes with effector memory phenotype. Each CD8+/Vβ+ expanded 
population has been shown to be the result of the proliferation of a clonal T cell bearing a 
defined TCR, as detected by analysis of TCR-V-Jγ rearrangement (Guida G et al, 2008). 
These CD8+/Vβ+ expanded populations have an effector memory (TEM) phenotype,  
as evidenced by flow cytometric analysis of CD45RA expression combined to CD62L,  
CCR7 or CD28 (Morice WG et al, 2004; Sallusto F et al, 1999). It has been suggested that 
circulating CD8+/Vβ+ TEM are antigen driven cells which may infiltrate target organs and 
participate to the inflammatory cascade of both vasculitic and granulomatous lesions  
(Guida G et al, 2008). 
A few preliminary reports (Boita M et al, 2010), showed an increased expression of CCR5 
and CXCR3 in CD8+ lymphocytes compared to healthy controls, both in V expanded 
families and in total CD8+ cells, suggesting Th1 polarization. On the other hand, increased 
expression of CCR4 and CRTH2 was present in CD4+ cells, suggesting Th2 polarization. An 
oligoclonal pattern was present in most V families of CD8+ lymphocytes, whereas the 
number of oligoclonal families of the CD4 subset was lower. TCR studies on cloned CD8 
lymphocytes showed the presence of a unique TCR in each of the expanded CD8+/Vbeta+ 
populations. 
Based on these preliminary data, it is hypotizable that monoclonal/oligoclonal expanded 
populations of effector CD8+ lymphocytes with a Th1/proinflammatory profile are 
involved in vasculitic damage, whereas CD4+ cells with a Th2 profile mediate eosinophil-
rich inflammation and asthma.  
5.2 The role of ANCA and B cells 
Antineutrophil cytoplasmic antibodies (ANCA) are predominantly IgG autoantibodies 
directed against constituents of primary granules of neutrophils and monocytes’ lysosomes. 
They exist in two forms: c-ANCA that has a Immuno Fluorescent (IF) citoplasmatic pattern 
against proteinase-3 (Pr-3) and p- ANCA that consists of a IF perinuclear pattern directed 
against myeloperoxidase (MPO). In studies with large cohort of patients with small vessel 
vasculitis, ANCA were detected in about 38-59% of patients with Churg–Strauss syndrome 
(Guillevine L et al, 1999; Cohen P et al, 1995). ANCA appearance might precede CSS clinical 
onset in some patients, but the primum movens for their synthesis remains unknown. In this 
context, B cells could play a role as autoreactive cells producing ANCA auto antibodies. 
There is no uniform theory explaining how ANCA may cause pauci-immune vasculitides 
but the common pathogenetic model suggests that binding of ANCA causes activation  
of neutrophils, with subsequent increased adhesion and migration to endothelium, release 
of proteolytic granule enzymes and proinflammatory cytokines, generation of respiratory 
burst, and, eventually, endothelial cell damage. ANCA-mediated neutrophil activation 
disrupts apoptosis of neutrophils which undergo secondary necrosis with subsequent 
release of inflammatory mediators, hence amplifying the process (Csernok E, 2003) . ANCA 
promote the interaction between neutrophils and endothelial cells through β2 integrins 
(CD11a/CD18 and CD11b/CD18) and GTP binding protein chemokine receptors. 
Afterwards, noxious neutrophils’ constituents—reactive oxygen species and proteolytic 
enzymes—are secreted, damaging vessel walls. Proinflammatory cytokines secreted  
by neutrophils as a result of ANCA binding include IL-1β, TNF-α, IL-6, IL-8, monocyte 
chemoattractant protein 1, and leukotriene B4. ANCA-mediated cytokine secretion  
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will activate and recruit inflammatory cells, amplifying and perpetuating the inflamatory 
response, with monocytes and T cells participating later in the process (Jennette JC  
et al, 2006).  
5.3 The role of eosinophils 
CSS is defined by blood eosinophilia usually >10% and eosinophilic infiltration into affected 
tissues. According to this, IL-5 and other Th2 cytokines may in fact play an important role in 
the pathogenesis of CSS. 
The production of IL-5 and other cytokines before and after stimulation with T cell–specific 
stimuli (anti- CD3 and anti-CD28) have been analyzed in peripheral blood mononuclear 
cells (PBMCs) obtained from patients with CSS, showing significant increased IL-5 level in 
CSS compared with healthy controls. However, IL-5 production in PBMCs cultured without 
T cell–specific stimuli (anti-CD3) and costimulatory signals (anti-CD28) was low both in CSS 
patients and controls suggesting that PBMCs in CSS require T cell activation to secrete large 
amounts of IL-5 (Kiene M et al, 2001; Hellmick B, 2005).  
IL5 is the most potent cytokine which induces terminal differentiation of committed 
eosinophil precursors. Moreover, IL-5 prolongs the survival of mature eosinophils. In 
addition, IL-5 activates mature eosinophils and selectively induces degranulation and 
antibody-dependent cytotoxicity of eosinophils. Of particular interest with regard to the 
pathogenesis of CSS and vasculitis is the capability of IL-5 to promote the adhesion of 
eosinophils to vascular endothelium and CC chemokine receptor 3 (CCR3)–dependent 
migration of eosinophils from the vasculature into the tissues. 
Because organ damage in CSS is at least partially mediated by direct invasion and 
degranulation of eosinophils into the tissues, other mediators than IL-5 might also be 
important. Recently, a chemokine family specifically mediating trafficking of eosinophils to 
inflammatory sites has been characterized. Currently, CCL11, CCL24, and CCL26 are 
grouped together as eotaxins. They all bind to a common receptor CCR3. As to be expected 
for eosinophil chemotactic proteins, eotaxins are induced by Th-2 associated cytokines such 
as IL-4 and IL-13. Heavy tissue eosinophilia is found in most biopsies from active CSS 
patients. Serum eotaxin-3, but not eotaxin-1 and eotaxin-2, levels have been found greatly 
elevated in active CSS patients compared to healthy controls. The elevated eotaxin-3 serum 
levels rapidly decreased upon efficient immunosuppression (Polzer K et al, 2008). Thus, 
eotaxin-3 constitutes a possible target for the pharmacotherapy of CSS. 
6. Markers of disease 
The CHCC classification introduced the concept of surrogate markers of vasculitis but a list 
of markers was not provided and ANCA were not included. Conflicting results of studies 
relating titers of ANCA to disease activity of ANCA associated vasculitides (ASV) have been 
reported. A recent retrospective study suggested that acute rise in ANCA titer is highly 
predictive of a relapse of ASV (Lurati-Ruiz F et al, 2005; Baldini C et al, 2009). When the 
ANCA titer remains positive during immunosuppressive treatment for induction of 
remission, relapses within 5 years are more likely to occur (Sanders JS et al, 2006).  
The presence of ANCA was associated with renal disease, peripheral neuropathy, and 
biopsy-proven vasculitis. Absence of ANCA was associated with heart involvement and 
fever. This demonstrates that ANCA-positive Churg–Strauss syndrome differs 
phenotypically from ANCA negative Churg–Strauss syndrome (Sable-Fourtassou R et al, 
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2005; Sinico RA et al, 2005). Furthermore, ANCA might possibly indicate more severe 
disease at diagnosis, as assessed by the proportion of patients with poor scores in FFS and 
the Birmingham vasculitis activity score (BVAS). 
Several research teams are attempting to identify reliable marker(s) of CSS activity. 
Promising markers of the disease are those referring to activity and survival of eosinophils, 
like serum eosinophil cationic protein (Guilpain P et al, 2007), IL-5 (Tsukadaira A et al, 1999) 
or eotaxin-3 (CCL26), an eosinotactic chemokine mainly expressed on vascular endothelial 
cells and dermal fibroblasts (Polzer K et al, 2008). 
Recently, serum levels of TARC have been reported to be significantly elevated in CSS 
patients with active disease, and to correlate with the clinical course of the disease and with 
the absolute eosinophil counts, as well as with IgE levels (Dallos T et al, 2010). No 
confirmatory data are otherwise reported about the role of other eosinophil survival related 
molecules and interaction with the endothelium. 
It has been suggested that the detection of clonal expanded peripheral V+/CD8+ T cell 
populations (assessed by flow cytometry combined to analysis of TCR-γ gene 
rearrangement) is stable over time and might be useful in the differential diagnosis of CSS, 
as suggested by the negative findings in asthmatic controls (Guida G et al, 2008). 
Many of these observations require further validation and all the above-mentioned 
laboratory tests are not yet widely available outside highly specialized centers. Attempts to 
individualize CSS subgroups remain highly valuable and may further help to elucidate and 
understand its different underlying physio-pathogenetic mechanisms. 
7. Clinical presentation and classification of severity 
The most typical clinical presentation of Churg-Strauss syndrome is the appearance of 
vasculitic manifestations in a patient with known allergic rhinitis, sinus polyposis, and late-
onset asthma, usually preexisting for 5-10 years. General symptoms (i.e., fever or weight 
loss), mononeuritis multiplex, and/or necrotic cutaneous purpura are the most frequent 
manifestations at disease onset, in combination with elevated blood eosinophilia and 
inflammatory syndrome. 
7.1 Systemic symptoms and laboratory findings 
Fever is quite frequent , as well weight loss, which is often great and might herald onset of the 
vasculitic phase, as do fatigue and malaise. Arthralgias are common, but frank arthritis is rare. 
Abnormal laboratory findings in patients with Churg-Strauss syndrome include anaemia, 
leukocytosis, increased peripheral blood eosinophil count, and a raised erythrocyte 
sedimentation rate. Rarely, eosinophilia is not present, and wide-ranging and rapid changes 
in eosinophil counts happen. Use of corticosteroids to treat asthma may result in failure to 
detect eosinophilia in a patient with undiagnosed Churg-Strauss syndrome. Blood 
chemistry and urinalysis findings might show occult renal disease. Antineutrophil 
cytoplasmic antibodies are present in more than half of patients with a perinuclear staining 
pattern. Antineutrophil cytoplasmic antibody-positivity needs to be confirmed by 
demonstration of anti-myeloperoxidase (MPO) antibodies in serum. 
7.2 Skin 
Skin lesions are common and variable, occurring 40-81% of CSS patients and being the 
presenting sign in 14% of the patients (Bosco L et al 2011). In the majority of these patients, 
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skin lesions allowed for the histopathological diagnosis of CSS. The most common clinical 
features are papulo-nodules with the histological picture of extravascular Churg-Strauss 
granuloma followed by purpuric and/or necrotic lesions in the lower limbs corresponding 
to small-vessel vasculitis with eosinophils. Less common lesions include urticarial lesions 
and livedo reticularis. Therefore, a high index of suspicion on skin lesions and the proper 
lesion selection for histological examination may be very important for early diagnosis of 
CSS. Clinical-pathological correlation is essential, as both clinical and histological features 
are not pathognomonic.  
7.3 Respiratory system  
Upper airway 
Overall, 80% of CSS patients have active sinonasal symptoms at the time of presentation and 
worsening of their nasal symptoms may be the main event leading to their diagnosis (Srouji 
I et al. 2008) . Nearly half CSS patients had undergone nasal surgery. Nasal symptoms that 
are of particolar interest are nasal obstruction , rhinorrhea , anosmia , and excessive 
sneezing . Other symptoms include nasal crusting, purulent nasal discharge, and epistaxis. 
Sinonasal symptoms are common at initial presentation of CSS, emphasizing the role of 
otolaryngologists in its diagnosis. Overall, CSS-related sinonasal morbidity is significant and 
comparable with that of the general rhinosinusitis population. It predominantly results from 
symptoms of allergic rhinitis, but a significant proportion of CSS patients also report milder 
forms of crusting, epistaxis, and of purulent sinusitis, symptoms which are more commonly 
attributed to patients with Wegener Granulomatosis. 
Asthma 
Asthma is one of the key features of Churg-Strauss syndrome, usually it is adult-onset 
asthma, preceded by sinusitis in all the patients and nasal polyposis in most of them. 
Asthma at its onset is generally severe and very poorly controlled. Atopy is present in more 
than half of patients. Onset of vasculitic symptoms is often accompanied by asthma 
exacerbation and lung involvement. After introducing the treatment and achieving stable 
remission, asthma severity/control and lung function tests improved, but systemic low-dose 
corticosteroid therapy is often required to maintain asthma control in most of CSS patients 
(Szczeklik W et al. 2011) . 
Lung involvement 
The lung is the most commonly involved organ. Pulmonary hemorrhage is much less 
common than in the other small-vessel vasculitides. At histopathologic analysis, both 
necrotizing small-vessel vasculitis and an eosinophil-rich inflammatory infiltrate with 
necrotizing granulomas are seen (Katzenstein AL 2000). The most common lung 
radiographic manifestations of CSS consist of transient, bilateral, nonsegmental areas of 
consolidation without predilection for any lung zone (Silva CI et al 2005) . The areas of 
consolidation can be transient, resembling Löffler syndrome, or predominantly peripheral , 
resembling chronic eosinophilic pneumonia or organizing pneumonia . The most common 
abnormality at high-resolution CT, seen in up to 90% of patients, is bilateral areas of 
ground-glass opacity or consolidation (Worthy SA et al 1998). These usually have a 
symmetric distribution and often a peripheral predominance; less commonly, they have a 
peri-bronchial or patchy random distribution . Another relatively common finding is the 
presence of septal lines, seen in approximately 50% of patients. Interlobular septal 
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thickening may reflect the presence of edema secondary to cardiac involvement or 
eosinophilic infiltration of the septa. 
7.4 Heart 
Cardiovascular involvement is the leading cause of morbidity and death in Churg-Strauss 
syndrome. Heart manifestations of Churg-Strauss syndrome (CSS) are varied. In the early 
stages of the disease, it is difficult to distinguish between lesions that are specific to CSS and 
those of other etiologies. A specific physiopathology that is not mediated by ANCA seems 
to be involved in the genesis of CSS-related heart lesions. A negative antineutrophil 
cytoplasmic antibodies (ANCA) test and much higher eosinophil counts distinguish patients 
with cardiac involvement from those without (Neumann T et al 2009). Detailed cardiac 
evaluation revealed a unexpectedly high prevalence (more than 50%) of cardiac 
involvement in CSS patients. Impaired left ventricular function, mild to severe valvular 
insufficiencies , and pericardial effusions are common findings in these patients. 
Endomyocarditis may be found by cardiac MRI, cardiac thrombus formation, and 
endomyocardial biopsy, and is associated with impaired cardiac function. After therapy, 
most patients may regain or maintain good cardiac function. However, patients with 
endomyocarditis have a more severe outcome. Cardiac MRI is a sensitive, non-invasive 
method to detect cardiac lesions in patients whose conventional investigations indicated no 
cardiac disease and to assess the extent of cardiac involvement in symptomatic patients. 
Cardiac MRI can help to evaluate the therapeutic effect of immunosuppressants in CSS 
(Marmursztejn J et al 2010) 
7.5 Central nervous system 
Central nervous system (CNS) involvement account for 20% of neuropathy in CSS, 
including arachnoid hemorrhage, cerebrovascular neuropathy, meningitis, and diffuse brain 
damage, which may respond to treatment with high dose of prednisone plus 
immunosuppressants (Zhang W et al 2009).  
7.6 Peripheral nervous system 
A peripheral neuropathy is seen in up to 75 percent of patients with CSS. Mononeuritis 
multiplex and distal symmetrical and asymmetrical sensorimotor neuropathy are equally 
frequent. Severe neuropathic pain may accompany the peripheral neuropathy. The 
diagnosis of polyneuropathy is based on clinical and electrophysiologic studies, but precise 
histology, immuno-histochemistry and morphometric study of the peripheral nerve biopsy 
may be decisive in establishing the diagnosis (Kararizou E et al 2011) . There may be 2 
pathogenetic mechanisms of neuropathy with CSS: ANCA-related vascular fibrinoid 
necrosis, and a toxic eosinophilic effect on nerve fibers which is independent of ANCA. 
Therapy targeting activated eosinophils may be a possible treatment for intractable 
neuropathy of CSS (Oka N et al. 2010). 
7.7 Gastrointestinal tract 
An eosinophilic gastroenteritis, characterized by abdominal pain, diarrhea, gastrointestinal 
bleeding, and colitis, may precede or coincide with the vasculitic phase of CSS. 
Gastrointestinal involvement may result in acute abdomen, acute acalculous cholecystitis, 
pancreatitis, mesenteric vasculitis, and bowel perforation due to necrotizing vasculitis (Rolla 
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G et al. 2007). Severe gastrointestinal tract involvement is a well-recognized important 
negative prognostic factor. With severe gastrointestinal disease, including intestinal 
bleeding, perforation, and pancreatitis, survival was approximately 65% at 78 months 
compared with nearly 90% without such involvement (Guillevin L et al 1999). 
7.8 Renal  
The frequency of renal involvement varies among studies , from 15 to 30% (Sinico RA et al. 
2006). A few patients have rapidly progressive or acute renal insufficiency (plasma 
creatinine concentration >1.4 mg/dL), while most patients have isolated proteinuria or 
microscopic hematuria. Nephrotic syndrome is rarely reported. In the severe cases, renal 
biopsy shows necrotizing glomerulonephritis. A positive test for antineutrophil cytoplasmic 
antibodies (ANCA) is found in all patients with glomerulonephritis. Systemic hypertension 
affects approximately 10 to 30 percent of patients with CSS and may reflect renal 
involvement with CSS or be a complication of glucocorticoid therapy. 
8. Assessment of prognosis 
The 1996 Five-Factor Score (FFS) for systemic necrotizing vasculitides (polyarteritis nodosa, 
microscopic polyangiitis , and Churg-Strauss syndrome ) is used to evaluate prognosis at 
diagnosis. Recently (Merkel PA et al 2009) the FFS have been revisited, including Wegener 
granulomatosis (Guillevin L et al 2011).Clinical, laboratory, and immunologic 
manifestations present at diagnosis of systemic necrotizing vasculitides for 1108 consecutive 
patients registered in the French Vasculitis Study Group database were evaluated.Overall 
mortality was 19.8% (219/1108); mortality for each of the systemic necrotizing vasculitides 
was: 27.5 % for microscopic polyangiitis, 24.6 % for polyarteritis nodosa,13.9 % for CSS and 
13.2 % for WG. The following factors were significantly associated with higher 5-year 
mortality: age >65 years, cardiac symptoms, gastrointestinal involvement, and renal 
insufficiency (stabilized peak creatinine ≥150 μmol/L). All were disease-specific (p < 0.001); 
the presence of each was accorded +1 point. Ear, nose, and throat (ENT) symptoms, 
affecting patients with WG and CSS, were associated with a lower relative risk of death, and 
their absence was scored +1 point (p < 0.001). Only renal insufficiency was retained (not 
proteinuria or microscopic hematuria) as impinging on outcome. According to the 2009 FFS, 
5-year mortality rates for scores of 0, 1, and ≥2 were 9%, 21% (p <0.005), and 40% (p < 
0.0001), respectively.The revised FFS for the 4 systemic necrotizing vasculitides now 
comprises 4 factors associated with poorer prognosis and 1 with better outcome. The 
retained items demonstrate that visceral involvement weighs heavily on outcome.  
9. Therapy  
9.1 Corticosteroids  
The primary therapy for CSS is systemic glucocorticoids. An additional immunosuppressive 
agent is typically added in patients with more advanced or refractory disease and in those 
whose disease flares with tapering of systemic glucocorticoids .  
Systemic glucocorticoid therapy is the most important treatment for CSS.Treatment is 
generally initiated with prednisone at a dose of 0.5 to 1.5 mg/kg per day, the higher dose 
used for patients with more severe vasculitis .Intravenous glucocorticoid (eg, 
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methylprednisolone 1 g daily for three days) is used for initial therapy, followed by oral 
glucocorticoid therapy in the most severe cases.  
The majority of patients with CSS achieve a remission with glucocorticoid therapy alone, but 
relapses were common, and up to one-third of patients require additional 
immunosuppressive therapy (Ribi C et al.). In CSS patients with an FFS of 0, survival is 
excellent, confirming the predictive value of the FFS in this disease. Once disease 
manifestations have come under control, the glucocorticoid dose is gradually tapered over 
approximately 12 to 18 months, as tolerated. Unfortunately, over the long term, most 
patients continued to take oral CS, which might explain the high rate of CS-related adverse 
events. 
9.2 Cyclophosphamide  
The addition of cyclophosphamide is recommended for patients with a "five factors score" of 
1, particularly in the presence of cardiac or central nervous system involvement . 
Cyclophosphamide may be administered orally every day or intravenously once a month . 
Extrapolating from Wegener's granulomatosis, outcomes with daily and monthly regimens 
were similar; a slightly greater risk of bladder toxicity with the daily regimen and a slightly 
greater risk of relapse with the monthly regimen have been noted. The duration of 
cyclophosphamide therapy remains controversial. When used to treat Wegener's 
granulomatosis, typically a six month regimen is used. 
9.3 Alternative immunosuppressive therapy  
An alternative regimen for patients with milder non life-threatening disease, would be 
initial treatment with glucocorticoids plus either azathioprine (Bosch X et al 2007) or 
methotrexate (De Groot K et al 2005). In the latter study of 100 patients with early systemic 
ANCA-positive vasculitides (including CSS) that compared glucocorticoids plus 
methotrexate with glucocorticoids plus cyclophosphamide, the remission success rate was 
similar at six months (90 and 94 percent, respectively). However, the methotrexate regimen 
was less successful for patients with more extensive disease or pulmonary involvement. 
Interferon-alpha appeared to be an effective and well-tolerated treatment for induction of 
remission in patients with refractory Churg-Strauss syndrome in a phase II study (Metzler C. 
et al 2008). . Recombinant interferon-alpha has been reported to be partially effective in the 
prevention of major relapses in patients with Churg-Strauss syndrome (Metzler C. et al 2010). 
Due to numerous side effects and infections during long-term administration its use should be 
restricted to patients with contraindications against conventional immunosuppressive 
therapies. 
9.4 Immunosoppressive maintenance tharapy 
Once remission is induced with cyclophosphamide and glucocorticoid therapy (which 
usually occurs within six to twelve months), patients are switched to maintenance therapy 
with less toxic immunosuppressive drugs, usually azathioprine or methotrexate, in 
combination with a tapering dose of glucocorticoids. For patients whose disease is not 
severe enough to require cyclophosphamide, but requires long-term therapy with moderate 
to high dose prednisone (more than 10 mg daily), an immunosuppressive agent is often 
added for a glucocorticoid sparing effect. 
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9.5 New promising therapeutic approach: the monoclonal antibodies 
Rituximab 
B cell depletion with rituximab has allowed remissions in relapsing or refractory 
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in small studies. A 
multicenter survey of rituximab therapy for refractory ANCA-associated vasculitis has been 
recently published (Jones RB et al. 2009). This permitted comparison of rituximab dosing 
regimens, the value of continuing immunosuppression, and investigation of ANCA and B 
cell levels as re-treatment biomarkers. Retrospective, standardized data collection from 65 
sequential patients receiving rituximab for refractory ANCA-associated vasculitis at 4 
centers in the UK was used. All patients achieved B cell depletion. Complete remission 
occurred in 49 of the 65 patients (75%), partial remission in 15 (23%), and no response in 1 
(2%). The prednisolone dosage was reduced from 12.5 mg/day (median) to 9.0 mg/day at 6 
months (P = 0.0006). Immunosuppressive therapy was withdrawn in 37 of 60 patients (62%). 
Twenty-eight of 49 patients who achieved full remission (57%) experienced relapse (median 
11.5 months). B cell return preceded relapse in 14 of 27 patients (52%). Although ANCA 
levels fell after rituximab therapy, relapse was not associated with ANCA positivity or a rise 
in ANCA levels. Neither the initial rituximab regimen (4 infusions of 375 mg/m(2) each 
given 1 week apart or 2 infusions of 1 gm each given 2 weeks apart) nor withdrawal of 
immunosuppressive therapy (37 of 60 patients [62%]) influenced the timing of relapse. 
Thirty-eight patients received>or=2 courses of rituximab, and complete remission was 
induced or maintained in 32 of them (84%). IgM levels fell, although IgG levels remained 
stable. Forty-six serious adverse events occurred, including 2 episodes of late-onset 
neutropenia, which were attributed to rituximab. Rituximab seems to be effective for 
inducing remission in refractory ANCA-associated vasculitis. Nevertheless, relapses may 
occurr, but re-treatment has been found effective and safe. ANCA and B cell levels lacked 
sufficient sensitivity to guide the timing of re-treatment. 
Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome has 
been reported (Bouldouyre MA et al 2009). 
Mepolizumab  
Levels of IL-5, a cytokine regulating eosinophils, can be increased in patients with CSS. 
Mepolizumab, a humanized monoclonal anti-IL-5 antibody, decreases steroid requirements 
in patients with non-CSS hypereosinophilic syndromes. Recently, whether mepolizumab 
would safely allow corticosteroid tapering in patients with steroid-dependent CSS while 
decreasing serum markers of disease activity has been investigated in an open-label pilot 
study (Kim S et al 2010). Seven patients received 4 monthly doses of mepolizumab to assess 
whether it safely decreased CSS disease activity and permitted tapering of systemic 
corticosteroids. Mepolizumab was safe and well tolerated in patients with CSS. 
Mepolizumab reduced eosinophil counts and allowed for safe corticosteroid reduction in all 
7 subjects. On cessation of mepolizumab, CSS manifestations recurred, necessitating 
corticosteroid bursts. Mepolizumab is a safe and well-tolerated therapy in patients with CSS, 
offering clinical benefit by enabling corticosteroid tapering while maintaining clinical 
stability. 
Omalizumab 
The anti-IgE monoclonal antibody omalizumab is approved as add-on therapy of severe 
allergic asthma . Besides the IgE blockage effect, studies have shown antiallergic and anti-
inflammatory properties of anti-IgE, among which is the reduction in circulating and tissue 
eosinophils. 
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Efficacy of omalizumab therapy in some cases of CSS have been reported. In two patients 
whose disease was not controlled by systemic glucocorticoid , omalizumab obtained disease 
control (Pabst S et al 2008). Another report described similar results with anti-IgE in a 
patient with Churg–Strauss syndrome (CSS) who still presented with asthma which was 
difficult to control. The asthma did not improve despite the use of high-dose inhaled 
corticosteroids, long-acting β2 agonists and several courses of steroid pulse therapy. 
Omalizumab was given and his asthma was controlled and a marked improvement in 
eosinophilia was observed (Giavina-Bianchi P et al 2007). 
On the other hand, there are at least three cases of temporal association between anti-IgE use 
and the development of CSS. CSS was probably caused by systemic steroid tapering in these 
cases, rather than anti-IgE use.  
Omalizumab can be used in patients with CSS to treat and control asthma, but it is probable 
that anti-IgE alone is not enough to control CSS activity. Although we are getting more 
evidence about the safety of omalizumab in patients with asthma and CSS, larger long-term 
studies are needed before the widespread use of anti-IgE can be recommended and also to 
verify if it is effective in the treatment of CSS. 
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